ZLY28 (oral; 20 mg/kg) significantly alleviates fatty liver by regulating multiple pathogeneses, including lipid metabolism, inflammation, oxidative stress, and fibrosis in the NASH mice model[1].
| Animal Model: | 8 weeks old male C57BL/6 mice[1] |
| Dosage: | 20 mg/kg |
| Administration: | Oral administration |
| Result: | Mainly distributed in the ileum with an ileum/plasma ratio of 104.1.
Significantly alleviated hepatic steatosis, lobular inflammation and ballooning.
Improved hepatic lipid homeostasis by inhibiting lipogenesis and promoting lipolysis.
Downregulated the gene expression levels.
Exhibited an acceptable safety profile with no acute toxicity.
|
